Literature DB >> 18640002

The management of papillary lesion of the breast by core needle biopsy.

H S Tseng1, Y L Chen, S T Chen, Y C Wu, S J Kuo, L S Chen, H K Wu, D R Chen.   

Abstract

BACKGROUND: The purpose of this study was to determine the accuracy of core needle biopsy (CNB) diagnoses of papillary breast lesions, and to identify the risk factors and histologic features, compared with excisional biopsy (EB).
METHOD: We retrospectively reviewed 1,682 sonographically guided core needle biopsies performed at one single medical center from January 2001 through December 2005, and identified 41 papillary lesions. Surgical correlation was available for 35 cases, 2 cases were loss follow-up and 4 cases diagnosed as papilloma by core needle biopsy were followed up with imaging for at least 24 months.
RESULTS: The pathologic diagnoses for the 35 papillary lesions obtained at core biopsy were benign in 24 cases, atypical in 7, and malignant in 4. Of those diagnosed as benign lesions at CNB, 7/24 turned out to be malignant. In the hyperplasia group, 5/7 were malignant. The total upgrade rate was 39%. The positive predict value was 100% and negative predict value was 61%.
CONCLUSION: All papillary lesions of the breast diagnosed by CNB should be excised because a substantial number of lesions were upgraded of diagnoses at excision.

Entities:  

Mesh:

Year:  2008        PMID: 18640002     DOI: 10.1016/j.ejso.2008.06.004

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

1.  Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision.

Authors:  Anupma Nayak; Selin Carkaci; Michael Z Gilcrease; Ping Liu; Lavinia P Middleton; Roland L Bassett; Jinxia Zhang; Hong Zhang; Robin L Coyne; Therese B Bevers; Nour Sneige; Lei Huo
Journal:  Clin Breast Cancer       Date:  2013-10-08       Impact factor: 3.225

Review 2.  MR imaging findings of benign and malignant circumscribed breast masses: part 2. Cystic circumscribed masses.

Authors:  Takayoshi Uematsu; Masako Kasami
Journal:  Jpn J Radiol       Date:  2009-12-25       Impact factor: 2.374

Review 3.  Non-malignant breast papillary lesions - b3 diagnosed on ultrasound--guided 14-gauge needle core biopsy: analysis of 114 cases from a single institution and review of the literature.

Authors:  Simonetta Bianchi; Benedetta Bendinelli; Valeria Saladino; Vania Vezzosi; Beniamino Brancato; Jacopo Nori; Domenico Palli
Journal:  Pathol Oncol Res       Date:  2015-01-10       Impact factor: 3.201

Review 4.  Vacuum-assisted breast biopsy for breast cancer.

Authors:  Hai-Lin Park; Jisun Hong
Journal:  Gland Surg       Date:  2014-05

5.  Benign breast papillary lesions diagnosed on core biopsy: upgrade rate and risk factors associated with malignancy on surgical excision.

Authors:  Christine MacColl; Amir Salehi; Sameer Parpia; Nicole Hodgson; Milita Ramonas; Phillip Williams
Journal:  Virchows Arch       Date:  2019-08-01       Impact factor: 4.064

6.  Analysis of false-negative results after US-guided 14-gauge core needle breast biopsy.

Authors:  Ji Hyun Youk; Eun-Kyung Kim; Min Jung Kim; Jin Young Kwak; Eun Ju Son
Journal:  Eur Radiol       Date:  2009-10-28       Impact factor: 5.315

Review 7.  Papillary neoplasms of the breast-reviewing the spectrum.

Authors:  Timothy Kwang Yong Tay; Puay Hoon Tan
Journal:  Mod Pathol       Date:  2021-01-18       Impact factor: 7.842

8.  A retrospective observational study of intraductal breast papilloma and its coexisting lesions: A real-world experience.

Authors:  Xiaona Li; Huan Wang; Zhe Sun; Chuifeng Fan; Feng Jin; Xiaoyun Mao
Journal:  Cancer Med       Date:  2020-08-21       Impact factor: 4.452

9.  Breast papillary lesions: an analysis of 70 cases.

Authors:  Dahiana Pulgar Boin; Jaime Jans Baez; Militza Petric Guajardo; David Oddo Benavides; Maria Elena Navarro Ortega; Dravna Razmilic Valdés; Mauricio Camus Apphun
Journal:  Ecancermedicalscience       Date:  2014-09-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.